Impact of Sars-CoV-2 prophylaxis with tixagevimab-cilgavimab in high-risk patients with B-cell malignancies: a single-center retrospective study. (2023). Mediterranean Journal of Hematology and Infectious Diseases, 15(1), e2023061. https://doi.org/10.4084/MJHID.2023.061